1.结直肠锯齿状病变中RUNX3的表达及其基因多态性的观察研究；2.结直肠纤维绒毛锯齿状腺瘤的病理形态学及免疫组织化学特征
|
摘要
[背景与目的]
锯齿状病变是一组以上皮呈锯齿状结构为特征的结直肠息肉/腺瘤,因其具有恶变为结直肠腺癌的潜能,近年来日益受到临床病理学工作者的关注。2010年新版WHO消化系统肿瘤分册将锯齿状息肉和息肉病明确分为增生性息肉(Hyperplastic polyps,HPs),广基锯齿状腺瘤/息肉(Sessile serrated adenoma/polyp,SSA/P),传统锯齿状腺瘤(Traditional serrated adenoma,TSA)三种类型。其中TSA和SSA具有明确恶变潜能,不同类型的HPs与也有类似于TSA及SSA的基因改变。锯齿状通路是一个多因素、多阶段、多基因改变渐进性累积的复杂过程,在此演变过程中涉及多种癌基因和抑癌基因,具体的发病机制迄今未完全明了。Runx转录因子3 (Runt-related transcription factor 3,RUNX3)基因是近年来新发现的一种抑癌基因,已被证实在多种人类肿瘤中存在RUNX3基因的异常。有研究发现RUNX3基因与人类消化系统肿瘤的发生关系更为密切,但是RUNX3基因在锯齿状病变发生和恶变过程中的作用尚不明确。
RUNX3位于人类染色体的1p36.1,主要表达于消化道上皮细胞、血液细胞、间叶细胞、神经细胞等。已有研究证实RUNX3基因通过调节细胞周期和诱导细胞凋亡对肿瘤造成抑制,RUNX3基因的失活可能会造成癌症的发生。目前关于RUNX3在结肠癌中的作用已有不少文献,但有关RUNX3在锯齿状病变中作用的研究报告很少,国外Subramaniam等曾通过免疫组织化学方法比较发现HP和TSA中RUNX3的阳性表达较正常结肠组织和管状腺瘤(Tubular adenoma,TA)中有所下降,而国内尚没有对RUNX3在锯齿状病变中的研究报告。
本研究通过观察锯齿状病变在RUNX3的免疫组织化学表达以及分析锯齿状腺瘤(Serrated adenoma,SA)中RUNX3(rs2236851,C/T)位点多态性,并观察上述两者的关系,从而对RUNX3在锯齿状病变发生与癌变途径中的作用进行初步探讨。
[方法]
收集北京军区总医院、海军总医院、解放军第二五二医院、河北省巨鹿县医院、北京中医药大学东直门医院2002年10月至2009年9月间病理诊断为结直肠各类息肉和腺瘤切片共5347例,所有切片按WHO及文献标准,3名病理医师4—5轮阅片,从中筛选出锯齿状病变共258例。对上述258例锯齿状病变进行组织学诊断及分类,从中筛选出TSA32例,SSA/P 8例,HP25例,并收集大肠癌(Colorectal cancer,CRC) 20例、TA25例、正常大肠组织25例作为对照组,所有组织切片均进行免疫组织化学染色,观察RUNX3的表达情况。另从上述258例锯齿状病变中随机挑选出50例SA(包括TSA40例,SSA/P10例)作为实验组,并收集正常大肠组织20例作为正常对照组,运用PCR-SSP方法研究RUNX3(rs2236851,C/T)的多态性;并从SA实验组中随机抽取30例SA进行免疫组织化学染色,运用IPP图像分析系统进行免疫组织化学阳性表达的半定量分析,分析基因型与RUNX3表达之间的关系。
[结果]
对RUNX3在正常组、TA组、HP组、TSA组、SSA组以及CRC组的免疫组织化学表达进行统计学分析,结果显示:RUNX3在TSA、SSA、大肠癌三组阳性率比正常对照组明显降低,差异具有统计学意义;RUNX3在SSA组与TA组之间、CRC组与TA组之间也具有统计学差异。TSA组与TA组之间虽然没有统计学差异,但TSA组RUNX3阳性表达率明显低于TA组。对RUX3基因rs2236851位点多态性分析及IPP图像分析系统半定量分析显示:SA实验组T等位基因的频率明显高于正常对照组,RUNX3基因rs2236851位点可能与SA密切相关;分析SA基因型与RUNX3表达的关系发现TC基因型SA患者的RUNX3阳性表达明显降低。
[结论]
1.免疫组织化学结果显示RUNX3在锯齿状病变中表达阳性率降低,提示其可能是SA发生和恶变过程中的必要条件。
2.基因多态性分析结果提示RUNX3 (rs2236851, C/T)位点可能与SA密切相关,TC基因型SA患者的RUNX3阳性表达降低更明显。
[背景与目的]
锯齿状病变是一组以上皮呈锯齿状结构为特征的结直肠息肉/腺瘤。2010年版WHO消化系统肿瘤分册将锯齿状病变明确分为增生性息肉(Hyperplastic polyps,HPs),广基锯齿状腺瘤/息肉(Sessile serrated adenoma/ polyp,SSA/P),传统锯齿状腺瘤(Traditional serrated adenoma,TSA)三种类型。其中HP根据粘液类型又分为微小泡状型HP(microvesicula HP,MVHP)、杯状细胞型HP(goblet cellric HP,GCHP)、粘液缺乏型HP(mucin poor HP,MPHP);SSA/P根据细胞异型性分为不伴细胞异型增生型SSA/P及伴有细胞异型增生型SSA/P。近来,在锯齿状病变中,有研究者发现存在一类形态更为特殊的锯齿状病变,其形态除具有典型的锯齿状结构外,还兼有长纤维绒毛状突起的特征。2010年版WHO消化系统肿瘤分册将这类锯齿状病变归为TSA中较罕见的一个亚型,称作“纤维绒毛锯齿状腺瘤”(Filiform serrated adenoma,FSA)。目前国内外对FSA的了解与研究甚少,多数病理及临床医师对其更是鲜有认识。因此本研究通过探讨FSA的临床病理学形态学特征以及免疫组织化学特征,旨在增强对FSA的认识,加强对患者的预后管理。
[方法]
收集北京军区总医院、海军总医院、解放军第二五二医院、河北省巨鹿县医院、北京中医药大学东直门医院2002年10月至2009年9月间病理诊断为结直肠各类息肉和腺瘤切片5347例,所有切片按WHO及文献标准,3名病理医师4-5轮阅片,从中筛选出FSA共18例,同时收集临床相关资料并观察病理学特征。对FSA11例,NFSA20例(其中TSA15例, SSA/P5例),HP20例,VTA20例分别进行免疫组化Ki-67、p53、β-Catenin、CK7、CK20、CDX-2、RUNX3染色。
[结果]
观察结果显示FSA占所收集全部结直肠息肉/腺瘤的0.34%,占锯齿状病变的6.98%;FSA多发于老年人,部位多位于左半结肠,尤其直肠部位。组织学观察结果显示其表面可见许多细长的纤维状绒毛状突起,隐窝被覆有异型增生的上皮细胞,伴有典型锯齿状改变;该类突起形似绒毛管状腺瘤,但其长度比绒毛管状腺瘤长;多数病例的突起末端可见明显间质水肿,严重者膨大呈“球茎”状改变;FSA异型增生程度较NFSA、VTA要高,差异有统计学意义。免疫组织化学染色结果显示p53、Ki-67、RUNX3在FSA中的表达与其他组间存在统计学差异;β-Catenin、CK7、CK20、CDX-2在FSA中的表达与其他组间未见统计学差异。
[结论]
1.FSA是特殊类型的锯齿状腺瘤,多发于左半结肠尤其直肠部位。
2.病理形态学观察结果提示FSA以“长纤维绒毛”的典型特征区别于其他锯齿状病变。与NFSA、VTA相比,其异型增生程度更高。
3.免疫组织化学结果提示FSA具有较高增殖活性,Ki-67在FSA中的表达提示FSA可能具有更高的恶变潜能。
[Background and Objective]
Serrated lesions are a group of colorectal adenoma/polyps characterized morphologically by a serrated architecture of the crypt epithelium.Because of their malignant potential, serrated lesions become Research focus and get more attention by clinical Pathologist in recent years.The lesions include hyperplastic polyps(HPs),sessile serrated adenoma/ polyp (SSA/P) and traditional serrated adenoma(TSA) in WHO(2010).TSA and SSA have malignant potential,and different types of HPs also has similar genetic changes like TSA and SSA. Runt-related transcription factor 3 (Runx3) is considered to be a tumor suppressor gene, and have been found that there are RUNX3 gene abnormalities in variety human tumors in recent years. Studies have found that Runx3 is more closely related with human digestive system tumors, But the effection of RUNX3 gene in serrated lesions is not clear.
RUNX3 is located on human chromosome 1p36.1,mainly express in gastrointestinal epithelium cells, blood cells, mesenchymal, nerve cells, etc. Research showed RUNX3 could inhibit growth of tumors by regulate cell cycle and induce apoptosis of tumor cell. In this study,the immunohistochemical expression and genetic polymorphism analysis of RUNX3 were observed in serrated lesions, the relationship between them were discussed, and the effection of RUNX3 in serrated pathway were explored.
[Methods]
A total of 5347 cases of colorectal polyps from five hospitals during a five-year period were retrospectively reviewed. The serrated lesions were classified based on WHO standards and literature. Amongst 5347 colorectal polyps studied,258 cases of serrated lesions were found. Amongst 258 cases of serrated lesions,32 cases of TSA, 8 cases of SSA/P and 25 cases of HP were selected. 25 cases of TA, 25 cases of normal colorectal tissues and 20cases of invasive adenocarcinoma were selected as the controls.All tissue sections were stainned using RUNX3 antibody by immunohistochemical methods.Besides, 50 cases of SA (including 40 cases of SA and 10 cases of SSA/P) and 20 cases of normal colorectal tissues were selected as the controls.Polymorphisms of RUNX3(rs2236851,C/T ) were genotyped by PCR-SSP. The relationship between immunohistochemical expression and genetic polymorphism were explored by IPP methods.
[Results]
The positive rate of RUNX3 in TSA,SSA and CRC were lower than in normal group.There were significant differences between the TSA,SSA,CRC and normal group.The significant differences also were observed between SSA,CRC and TA.The study of RUNX3 (rs2236851,C/T) polymorphism and the semi-quantitative analysis using IPP software was showed that the frequency of T allele was significantly higher in serrated adenoma(SA) than the normal control group. The RUNX3(rs2236851,C/T) was closely related with SA and the immunohistochemical expression of RUNX3 was lower in SA with TC genotype.
[Conclusions]
1. Immunohistochemistry expression results showed that the positive rate of RUNX3 expression is reduced in serrated lesions.It was a necessary events for SA changing into malignant lesions.
2. The results of RUNX3 genetic polymorphism analysis suggest that RUNX3 (rs2236851, C / T) was closely related with the SA, the expression of RUNX3 in SA (TC genotype) was reduced.
[Background and Objective]
Serrated lesions are a heterogeneous group of lesions characterized morphologically by a serrated architecture of the epithelial compartment.The lesions include hyperplastic polyps(HPs),sessile serrated adenoma/ polyp (SSA/P) and traditional serrated adenoma(TSA) in WHO(2010). according to the type of mucus, HPs were divided into microvesicula HP (MVHP), goblet cellric HP (GCHP) and mucin poor HP ( MPHP). And according to cell atypia, the SSA/P were divided into SSA/P with dysplasia and SSA/P without dysplasia.
Some studies reported an unusual type of TSA with long filiform projections lined by neoplastic epithelium with a serrated contour. These lesions were called Filiform Serrated Adenoma (FSA) in WHO( 2010). At present, domestic and international research with FSA is uncommon and the knowledge about these lesions was little understanding among clinical physicians and pathologists. Most of the pathological and clinical physicians to understand it even less.Therefore, this study discusses the clinical and pathological features of FSA and explore the immunohistochemical chang. Aim to help clinical pathologists enhanced understanding of FSA and to improve the management of patients.
[Methods]
A total of 5347 cases of colorectal polyps/adenomas from five regional hospitals in five years were retrospectively reviewed and 18 cases of FSA were selected. 20 cases of NFSA(including 15 cases TSA and 5 cases of SSA/P),20 cases of HP and 20 cases of VTA were randomly selected as control group. The clinical pathologic feature of FSA were observed.The expression of Ki-67, p53, CK7,CK20, CDX2, beta-catenin and RUNX3 in FSA,NFSA,HP and VTA were compared by immunohistochemical stain.
[Results]
Observation of clinical feature showed that FSA account for 0.34% of 5347 colorectal polyps/adenomas and account for 6.98% of 258 serrated lesions.FSA was tend to occur in older adults, and showed a strong predilection for developing in the left colon, especially the rectum. Observation of pathological features showed that FSA with long filiform projections lined by neoplastic epithelium with a serrated contour. The filiform projections of FSA were longer than the villi present in typical VTA .Marked stromal edema was present and the "bulb"-like change was showed in swelling of Severe cases. There was statistically significant difference between FSA and NFSA in the degree of dysphasia(p<0.05). The expression of Ki-67,p53,RUNX3 showed significant difference among FSA ,NFSA,HP and VTA (P<0.05); while the difference among expression ofCK7,CK20,CDX2 and beta-catenin in FSA ,NFSA,HP and VTA were not observed (P>0.05).
[Conclusions]
1. Observation showed that FSA is an uncommon type of serrated adenoma, shows a strong predilection located in the left colon,especially in rectum.
2. Pathological observation results show that FSA has long filiform projections lined by neoplastic epithelium with a serrated contour unlike traditionalSA,.
3. Immunohistochemical results suggest that FSA may has higher proliferation activity and higher malignant transformation potential.
锯齿状病变是一组以上皮呈锯齿状结构为特征的结直肠息肉/腺瘤,因其具有恶变为结直肠腺癌的潜能,近年来日益受到临床病理学工作者的关注。2010年新版WHO消化系统肿瘤分册将锯齿状息肉和息肉病明确分为增生性息肉(Hyperplastic polyps,HPs),广基锯齿状腺瘤/息肉(Sessile serrated adenoma/polyp,SSA/P),传统锯齿状腺瘤(Traditional serrated adenoma,TSA)三种类型。其中TSA和SSA具有明确恶变潜能,不同类型的HPs与也有类似于TSA及SSA的基因改变。锯齿状通路是一个多因素、多阶段、多基因改变渐进性累积的复杂过程,在此演变过程中涉及多种癌基因和抑癌基因,具体的发病机制迄今未完全明了。Runx转录因子3 (Runt-related transcription factor 3,RUNX3)基因是近年来新发现的一种抑癌基因,已被证实在多种人类肿瘤中存在RUNX3基因的异常。有研究发现RUNX3基因与人类消化系统肿瘤的发生关系更为密切,但是RUNX3基因在锯齿状病变发生和恶变过程中的作用尚不明确。
RUNX3位于人类染色体的1p36.1,主要表达于消化道上皮细胞、血液细胞、间叶细胞、神经细胞等。已有研究证实RUNX3基因通过调节细胞周期和诱导细胞凋亡对肿瘤造成抑制,RUNX3基因的失活可能会造成癌症的发生。目前关于RUNX3在结肠癌中的作用已有不少文献,但有关RUNX3在锯齿状病变中作用的研究报告很少,国外Subramaniam等曾通过免疫组织化学方法比较发现HP和TSA中RUNX3的阳性表达较正常结肠组织和管状腺瘤(Tubular adenoma,TA)中有所下降,而国内尚没有对RUNX3在锯齿状病变中的研究报告。
本研究通过观察锯齿状病变在RUNX3的免疫组织化学表达以及分析锯齿状腺瘤(Serrated adenoma,SA)中RUNX3(rs2236851,C/T)位点多态性,并观察上述两者的关系,从而对RUNX3在锯齿状病变发生与癌变途径中的作用进行初步探讨。
[方法]
收集北京军区总医院、海军总医院、解放军第二五二医院、河北省巨鹿县医院、北京中医药大学东直门医院2002年10月至2009年9月间病理诊断为结直肠各类息肉和腺瘤切片共5347例,所有切片按WHO及文献标准,3名病理医师4—5轮阅片,从中筛选出锯齿状病变共258例。对上述258例锯齿状病变进行组织学诊断及分类,从中筛选出TSA32例,SSA/P 8例,HP25例,并收集大肠癌(Colorectal cancer,CRC) 20例、TA25例、正常大肠组织25例作为对照组,所有组织切片均进行免疫组织化学染色,观察RUNX3的表达情况。另从上述258例锯齿状病变中随机挑选出50例SA(包括TSA40例,SSA/P10例)作为实验组,并收集正常大肠组织20例作为正常对照组,运用PCR-SSP方法研究RUNX3(rs2236851,C/T)的多态性;并从SA实验组中随机抽取30例SA进行免疫组织化学染色,运用IPP图像分析系统进行免疫组织化学阳性表达的半定量分析,分析基因型与RUNX3表达之间的关系。
[结果]
对RUNX3在正常组、TA组、HP组、TSA组、SSA组以及CRC组的免疫组织化学表达进行统计学分析,结果显示:RUNX3在TSA、SSA、大肠癌三组阳性率比正常对照组明显降低,差异具有统计学意义;RUNX3在SSA组与TA组之间、CRC组与TA组之间也具有统计学差异。TSA组与TA组之间虽然没有统计学差异,但TSA组RUNX3阳性表达率明显低于TA组。对RUX3基因rs2236851位点多态性分析及IPP图像分析系统半定量分析显示:SA实验组T等位基因的频率明显高于正常对照组,RUNX3基因rs2236851位点可能与SA密切相关;分析SA基因型与RUNX3表达的关系发现TC基因型SA患者的RUNX3阳性表达明显降低。
[结论]
1.免疫组织化学结果显示RUNX3在锯齿状病变中表达阳性率降低,提示其可能是SA发生和恶变过程中的必要条件。
2.基因多态性分析结果提示RUNX3 (rs2236851, C/T)位点可能与SA密切相关,TC基因型SA患者的RUNX3阳性表达降低更明显。
[背景与目的]
锯齿状病变是一组以上皮呈锯齿状结构为特征的结直肠息肉/腺瘤。2010年版WHO消化系统肿瘤分册将锯齿状病变明确分为增生性息肉(Hyperplastic polyps,HPs),广基锯齿状腺瘤/息肉(Sessile serrated adenoma/ polyp,SSA/P),传统锯齿状腺瘤(Traditional serrated adenoma,TSA)三种类型。其中HP根据粘液类型又分为微小泡状型HP(microvesicula HP,MVHP)、杯状细胞型HP(goblet cellric HP,GCHP)、粘液缺乏型HP(mucin poor HP,MPHP);SSA/P根据细胞异型性分为不伴细胞异型增生型SSA/P及伴有细胞异型增生型SSA/P。近来,在锯齿状病变中,有研究者发现存在一类形态更为特殊的锯齿状病变,其形态除具有典型的锯齿状结构外,还兼有长纤维绒毛状突起的特征。2010年版WHO消化系统肿瘤分册将这类锯齿状病变归为TSA中较罕见的一个亚型,称作“纤维绒毛锯齿状腺瘤”(Filiform serrated adenoma,FSA)。目前国内外对FSA的了解与研究甚少,多数病理及临床医师对其更是鲜有认识。因此本研究通过探讨FSA的临床病理学形态学特征以及免疫组织化学特征,旨在增强对FSA的认识,加强对患者的预后管理。
[方法]
收集北京军区总医院、海军总医院、解放军第二五二医院、河北省巨鹿县医院、北京中医药大学东直门医院2002年10月至2009年9月间病理诊断为结直肠各类息肉和腺瘤切片5347例,所有切片按WHO及文献标准,3名病理医师4-5轮阅片,从中筛选出FSA共18例,同时收集临床相关资料并观察病理学特征。对FSA11例,NFSA20例(其中TSA15例, SSA/P5例),HP20例,VTA20例分别进行免疫组化Ki-67、p53、β-Catenin、CK7、CK20、CDX-2、RUNX3染色。
[结果]
观察结果显示FSA占所收集全部结直肠息肉/腺瘤的0.34%,占锯齿状病变的6.98%;FSA多发于老年人,部位多位于左半结肠,尤其直肠部位。组织学观察结果显示其表面可见许多细长的纤维状绒毛状突起,隐窝被覆有异型增生的上皮细胞,伴有典型锯齿状改变;该类突起形似绒毛管状腺瘤,但其长度比绒毛管状腺瘤长;多数病例的突起末端可见明显间质水肿,严重者膨大呈“球茎”状改变;FSA异型增生程度较NFSA、VTA要高,差异有统计学意义。免疫组织化学染色结果显示p53、Ki-67、RUNX3在FSA中的表达与其他组间存在统计学差异;β-Catenin、CK7、CK20、CDX-2在FSA中的表达与其他组间未见统计学差异。
[结论]
1.FSA是特殊类型的锯齿状腺瘤,多发于左半结肠尤其直肠部位。
2.病理形态学观察结果提示FSA以“长纤维绒毛”的典型特征区别于其他锯齿状病变。与NFSA、VTA相比,其异型增生程度更高。
3.免疫组织化学结果提示FSA具有较高增殖活性,Ki-67在FSA中的表达提示FSA可能具有更高的恶变潜能。
[Background and Objective]
Serrated lesions are a group of colorectal adenoma/polyps characterized morphologically by a serrated architecture of the crypt epithelium.Because of their malignant potential, serrated lesions become Research focus and get more attention by clinical Pathologist in recent years.The lesions include hyperplastic polyps(HPs),sessile serrated adenoma/ polyp (SSA/P) and traditional serrated adenoma(TSA) in WHO(2010).TSA and SSA have malignant potential,and different types of HPs also has similar genetic changes like TSA and SSA. Runt-related transcription factor 3 (Runx3) is considered to be a tumor suppressor gene, and have been found that there are RUNX3 gene abnormalities in variety human tumors in recent years. Studies have found that Runx3 is more closely related with human digestive system tumors, But the effection of RUNX3 gene in serrated lesions is not clear.
RUNX3 is located on human chromosome 1p36.1,mainly express in gastrointestinal epithelium cells, blood cells, mesenchymal, nerve cells, etc. Research showed RUNX3 could inhibit growth of tumors by regulate cell cycle and induce apoptosis of tumor cell. In this study,the immunohistochemical expression and genetic polymorphism analysis of RUNX3 were observed in serrated lesions, the relationship between them were discussed, and the effection of RUNX3 in serrated pathway were explored.
[Methods]
A total of 5347 cases of colorectal polyps from five hospitals during a five-year period were retrospectively reviewed. The serrated lesions were classified based on WHO standards and literature. Amongst 5347 colorectal polyps studied,258 cases of serrated lesions were found. Amongst 258 cases of serrated lesions,32 cases of TSA, 8 cases of SSA/P and 25 cases of HP were selected. 25 cases of TA, 25 cases of normal colorectal tissues and 20cases of invasive adenocarcinoma were selected as the controls.All tissue sections were stainned using RUNX3 antibody by immunohistochemical methods.Besides, 50 cases of SA (including 40 cases of SA and 10 cases of SSA/P) and 20 cases of normal colorectal tissues were selected as the controls.Polymorphisms of RUNX3(rs2236851,C/T ) were genotyped by PCR-SSP. The relationship between immunohistochemical expression and genetic polymorphism were explored by IPP methods.
[Results]
The positive rate of RUNX3 in TSA,SSA and CRC were lower than in normal group.There were significant differences between the TSA,SSA,CRC and normal group.The significant differences also were observed between SSA,CRC and TA.The study of RUNX3 (rs2236851,C/T) polymorphism and the semi-quantitative analysis using IPP software was showed that the frequency of T allele was significantly higher in serrated adenoma(SA) than the normal control group. The RUNX3(rs2236851,C/T) was closely related with SA and the immunohistochemical expression of RUNX3 was lower in SA with TC genotype.
[Conclusions]
1. Immunohistochemistry expression results showed that the positive rate of RUNX3 expression is reduced in serrated lesions.It was a necessary events for SA changing into malignant lesions.
2. The results of RUNX3 genetic polymorphism analysis suggest that RUNX3 (rs2236851, C / T) was closely related with the SA, the expression of RUNX3 in SA (TC genotype) was reduced.
[Background and Objective]
Serrated lesions are a heterogeneous group of lesions characterized morphologically by a serrated architecture of the epithelial compartment.The lesions include hyperplastic polyps(HPs),sessile serrated adenoma/ polyp (SSA/P) and traditional serrated adenoma(TSA) in WHO(2010). according to the type of mucus, HPs were divided into microvesicula HP (MVHP), goblet cellric HP (GCHP) and mucin poor HP ( MPHP). And according to cell atypia, the SSA/P were divided into SSA/P with dysplasia and SSA/P without dysplasia.
Some studies reported an unusual type of TSA with long filiform projections lined by neoplastic epithelium with a serrated contour. These lesions were called Filiform Serrated Adenoma (FSA) in WHO( 2010). At present, domestic and international research with FSA is uncommon and the knowledge about these lesions was little understanding among clinical physicians and pathologists. Most of the pathological and clinical physicians to understand it even less.Therefore, this study discusses the clinical and pathological features of FSA and explore the immunohistochemical chang. Aim to help clinical pathologists enhanced understanding of FSA and to improve the management of patients.
[Methods]
A total of 5347 cases of colorectal polyps/adenomas from five regional hospitals in five years were retrospectively reviewed and 18 cases of FSA were selected. 20 cases of NFSA(including 15 cases TSA and 5 cases of SSA/P),20 cases of HP and 20 cases of VTA were randomly selected as control group. The clinical pathologic feature of FSA were observed.The expression of Ki-67, p53, CK7,CK20, CDX2, beta-catenin and RUNX3 in FSA,NFSA,HP and VTA were compared by immunohistochemical stain.
[Results]
Observation of clinical feature showed that FSA account for 0.34% of 5347 colorectal polyps/adenomas and account for 6.98% of 258 serrated lesions.FSA was tend to occur in older adults, and showed a strong predilection for developing in the left colon, especially the rectum. Observation of pathological features showed that FSA with long filiform projections lined by neoplastic epithelium with a serrated contour. The filiform projections of FSA were longer than the villi present in typical VTA .Marked stromal edema was present and the "bulb"-like change was showed in swelling of Severe cases. There was statistically significant difference between FSA and NFSA in the degree of dysphasia(p<0.05). The expression of Ki-67,p53,RUNX3 showed significant difference among FSA ,NFSA,HP and VTA (P<0.05); while the difference among expression ofCK7,CK20,CDX2 and beta-catenin in FSA ,NFSA,HP and VTA were not observed (P>0.05).
[Conclusions]
1. Observation showed that FSA is an uncommon type of serrated adenoma, shows a strong predilection located in the left colon,especially in rectum.
2. Pathological observation results show that FSA has long filiform projections lined by neoplastic epithelium with a serrated contour unlike traditionalSA,.
3. Immunohistochemical results suggest that FSA may has higher proliferation activity and higher malignant transformation potential.
引文
[1]Snover DC.Update on the serrated pathway to colorectal carcinoma[J].Hum Pathol,2011,42(1):1-10.
[2] Snover DC, Ahnen DJ, But RW, et al.Serrated polyps of the colon and rectum and serrated polyposis[M].Pathology and Genetics Tumous and Digestive System. 2010:160-165.
[3]Li QL,Ito K,Sakakura C,et al.Causal relationship between the loss of RUNX3 expression and gastric cancer[J].Cell,2002,109(1):113-124.
[4]Manish M.Subramaniam MD,Jason Y,et al.RUNX3 Inactivation in Colorectal Polyps Arising Through Different Pathways of Colonic Carcinogenesis[J].Am J Gastroenterol,2009, 104(2):426-436.
[5]王鲁平,杨光之,周志勇等.结直肠锯齿状病变104例形态学及细胞增殖活性的观察[J].中华病理学杂志,2009,38(2): 100-105.
[6]Hamilton S, Vogelstein B, Kudo S,et al.Carcinoma of the colon and rectum[M]. Pathology and genetics tumors of the digestive system. 2000:105–143.
[7]Aust DE,Baretton GB.Serrated polyps of the colon and rectum (hyperplastic polyps, sessile serrated adenomas, traditional serrated adenomas,and mixed polyps)—proposal for diagnostic criteria[J].Virchows Arch,2010,457(3):291-297.
[8]Jass JR.Classification of colorectal cancer based on correlation of clinical, morphological and molecular features[J].Histopathology.2007,50(1):113–130.
[9]Kudo S,Lambert R,Allen JI,et al.Nonpolypoid neoplastic lesions of the colorectal mucosa[J]. Gastrointest Endosc.2008,68(4):S3–47.
[10]Torlakovic EE,Gomez JD,Driman DK,et al.Sessile serrated adenoma(SSA) vs traditional serrated adenoma(TSA)[J].Am J Surg Pathol,2008,32(1):21-29.
[11]East JE,Saunders BP,Jass JR.Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon:classification,molecular genetics,natural history,and clinical management[J].Gastroenterol Clin North Am,2008,37(1):25-46.
[12]王鲁平,陈健.与癌密切相关结直肠广基锯齿状腺瘤(SSA)的概念及病理诊断要点[J].诊断病理学杂志,2008,15(2):84-87.
[13]Changcun Guo, Fangfang Yao, Kaichun Wu,et al. Chromatin immunoprecipitation and association study revealed a possible role of Runt-related transcription factor 3 in the ulcerative colitis of Chinese population s[J]. Clinical Immunology,2010,135(3):483–489.
[14]许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,199,6(4):229-231.
[15]Ito Y,Miyazono K.RUNX transcription factors as key targets of TGF-beta superfamily signaling[J].Curr Opin Genet Dev,2003,13(1):43-47.
[16]Praml C,Finke LH,Herfarth C,et al.Deletion mapping defines different regions in 1p34.2-pter that may harbor genetic information related to human colorectal cancer[J]. Oncogene,1995,11(7):1357-62.
[17]Inoue K,Ozaki S,Shiga T,et al.Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons[J].Nat Neurosci,2002,5(10):946-954.
[18]Woolf E,Xiao C,Fainaru O,et al.Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis[J].Proc Natl Acad Sci U S A,2003,100(13):7731-7736.
[19]Levanon D,Bettoun D,Harris-Cerruti C,et al.The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons[J].EMBO J,2002,21(13):3454-3463.
[20]Markowitz SD,Roberts AB.Tumor suppressor activity of the TGF-beta pathway in human cancers[J].Cytokine Growth Factor Rev,1996,7(1):93-102.
[21]Zaidi SK,Sullivan AJ,van W ijnen AJ,et al.Integration of Runx and Smad regulatory signals at transcrip ttionally active subnuclear sites[J].Proc Natl Acad Sci USA,2002,99(12):8048-8053.
[22]Goel A,Arnold CN,Tassone P,et al.Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers[J].Int J Cancer,2004,112(5):754-759.
[23]Ku JL,Kang SB,Shin YK.et al.Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines[J].Oncogene,2004,23(40):6736-6742.
[24]Imamura Y,Hibi K,Koike M,et al.RUNX3 promoter region is specifically methylated in poorly-differentiated colorectal cancer[J].Anticancer Res,2005,25(4):2627-2630.
[25]Schulmann K,Sterian A,Berki A et al. Inactivation of p16,RUNX3,and HPP1 occurs early in Barrett’s-associated neoplastic progression and predicts progression risk[J].Oncogene,2005, 24(25):4138-4148.
[26]Park WS,Cho YG,Kim CJ,et al.Hypermethylation of the RUNX3 gene in hepatocellular carcinoma[J].Exp Mol Med,2005,37(4):276-281.
[27]Takahashi T,Shivapurkar N,Riquelme E.et al.Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis[J].Clin Cancer Res,2004,10(18pt1):6126-6133.
[28]Subramaniam MM,Chan JY,Soong R,et al.RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression[J].Breast Cancer Res Treat.2009,113(1):113-121.
[29]Yanada M,Yaoi T,Shimada J,et al.Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines[J].Oncol Rep,2005,14(4):817-822.
[30]Salto-Tellez M,Peh BK,Ito K.et al.RUNX3 protein is overexpressed in human basal cellcarcinomas[J].Oncogene,2006;25(58):7646-7649.
[31]李华,党荣良,袁权利等结肠癌组织中runx3、突变型p53蛋白的表达变化及意义[J].山东医药.2010,26 (50):56.
[32]Ito K,Liu Q,Salto-Tellez M,et al.RUNX3,a novel tumor suppressor,is frequently inactivated in gastric cancer by protein mislocalization[J].Cancer Res,2005,65(17):7743-7750.
[33]Lau QC,Raja E,Salto-Tellez M,et al.RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer[J]. Cancer Res,2006,66(13):6512-6520.
[34]Xu L,Massague J.Nucleocytoplasmic shuttling of signal transducers[J].Nat Rev Mol Cell Biol,2004,5(3):209-219.
[35]Tebutt NC,Giraud AS,Inglese M,et al.Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp 130 mutant mice[J].Nat Med,2002,8(10):1089-1097.
[1]Snover DC, Jass JR, Fenoglio-Preiser C, et al.Serrated polyps of the large intestine:a morphologic and molecular review of an evolving concept[J]. Am J Clin Pathol, 2005,124 (3):380-391.
[2]East JE, Saunders BP, Jass JR.Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon:classification,molecular genetics,natural history,and clinical management[J]. Gastroenterol Clin N Am,2008,37(1):25-46.
[3]Farris AB, Misdraji J, Srivastava A,et al. Sessile serrated adenoma:challenging discrimination from other serrated colonic polyps[J].Am J Surg Pathol,2008,32(1):30-35.
[4] Fred T Bosman,Fatima Carrneiro,Ralph H Hruban,et al.WHO Classification of Tumours of the Digestive System[M].International Agency for Research on Cancer,Lyon,2010:160-165.
[5] Yantiss RK, Oh KY, Chen YT,et al.Filiform serrated adenomas:a clinicopathologic and immunophenotypic study of 18 cases[J].Am J Surg Pathol,2007,31(8):1238-45.
[6] Owens SR,Chiosea SI,Kuan SF.Selective expression of gastric mcolonic sessile serrated adenoma hyperplastic polyp aids in morpdiagnosis of serrated polyps[J].Mod Pathol,2008,21 (6):660-9.
[7] Torlakovic EE,Gomez JD,Driman DK,et al.Sessile serrated adenoma(SSA) vs traditional serrated adenoma(TSA)[J].Am J Surg Pathol,2008,32(1):21-29.
[8] East JE,Saunders BP,Jass JR.Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon:classification,molecular genetics,natural history,and clinical management[J].Gastroenterol Clin North Am,2008,37(1):25-46.
[9]王鲁平,杨光之,周志勇等.结直肠锯齿状病变104例形态学及细胞增殖活性的观察[J].中华病理学杂志, 2009, 38(2): 100-105.
[10]王鲁平,陈健.与癌密切相关结直肠广基锯齿状腺瘤(SSA)的概念及病理诊断要点[J].诊断病理学杂志, 2008, 15(2):84-87.
[11] Maruyama K,Ochiai A,Akimoto S,et al.Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer[J].Oncology,2000,59(4):302-309.
[12]许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志, 1996, 6(4): 229-231.
[13]王鲁平,陈健,宁浩勇等.结直肠锯齿状病变发病情况及恶性潜能的病理学观察[J].中华病理学杂志,2010,39(7):447-451.
[14]Hiyama T,Yokozaki H,Shimamoto F,et al.Frequent p53 gene mutations in serrated adenomasof the colorectum[J].J Pathol,1998,186(2):131～139.
[15] Hiyama T,Yokozaki H,Shimamoto F,et al.Frequent p53 gene mutations in serrated adenomas of the colorectum[J].J Pathol,1998,186(2):131-139.
[16] Tateyama H,Li W,Takahashi E,et al.Apoptosis index and apoptosisrelated antigen expression in serrated adenoma of the colorectum:the saw-toothed structure may be related to inhibition of apoptosis[J].Am J Surg Pathol,2002,26(2):249-256.
[17]张宇,唐仁泉,张学义,等.p53、Bcl-2蛋白在锯齿状腺瘤的表达及临床意义[J].中外医疗,2008,24:61-62.
[18]代小娟,韩英,王鲁平.结直肠锯齿状腺瘤癌变潜能的研究[J].实用癌症杂志.2009,24 (5):548-550
[19] Oh K,Redston M,Odze RD.Support for hMLH1 and MGMT silencing as a mechanism of tumorigenesis in the hyperplasticadenoma-carcinoma(serrated) carcinogenic pathway in the colon[J].Hum Pathol,2005,36(1):101-111.
[20]Kirchner T, Muller S,Hattori T,ea tl.Metaplasia,intraepithelial neoplasia and early cancer of the stomach are related to differentiated epithelial cells defined by cytokeration-7 expressions in gastritis[J].Virchows Arch,2001,439(4):51-52.
[21]Tatsumi N, Mukaisho K,Mitsufuji S,ea tl. Expression of cytokeratins 7 and 20 in serrated adenoma and related diseases[J]. Dig Dis Sci, 2005,50(9):1741-1746.
[22]PeiferM.Wnt signaling in oneogenesis and embryogenesis a look outside the nucleus[J].Science,2000,287(5458):1606-1609.
[23]Hugh TJ,Dillon SA,Taylor BA,etal.Cadherin-catenin in espression in primary colorectal cancer:a survival analysis[J].Br J Cancer,1999,80(7):1046-1051.
[24]WongSC,LoES,LeeKC,et al.Prognostic and diagnostic significance of bête-catenin nuclear inmunostaining in colorectal cancer[J].Clin Caneer Res,2004,10(4):1401-1408.
[25]SuhE,Traber P.An intestine-specific homeobox gene regulates proliferation and differentiation[J].Mol Cel Biol,1996,16:619-625.
[26]Bla YQ,Miyake S,Iwai T,et a1.CDX2,a homoebox transcription factor,upregulates transcription of the p21/WAF1/C1P1gene [J].Oncogene,2003,22:7942-7949.
[27]Kim SP,Park JW,Lee SH,et a1.Homeodomain protein CDX2 regulates COX2 expression in colorectal cancer[J].Biochem Bio-phys Res Commun,2004,315:93—99.
[28] mamichi N,Inada K,Furukawa C,et al.Cdx2 and the Brm-type SWI/SNF complex cooperatively regulate villin expression in gastrointestinal cells[J].Exp Cell Res,2009,315 (10):1779-1789
[29] Gross I,Duluc I,Benameur T,et al.The intestine-specific homeobox gene Cdx2 decreases mobility and antagonizes dissemination of colon cancer cells[J].Oncogene,2008,27(1):107-115.
[30] Li QL,Ito K,Sakakura C,et al.Causal relationship between the loss of RUNX3 expression and gastric cancer[J].Cell,2002,109(1):113-124.
[31]Zaidi SK,Sullivan AJ,van W ijnen AJ,et al.Integration of Runx and Smad regulatory signals at transcrip ttionally active subnuclear sites[J].Proc Natl Acad Sci USA,2002,99(12):8048-8053.
[32] Subramaniam MM,Chan JY,Soonq R.RUNX3 inactivation in colorectal polyp s arising through different pathways of colonic carcinogenesis[J].Am J Gastroenterol,2009,104(2):426.
[1]Snover DC. Update on the serrated pathway to colorectal carcinoma[J].Hum Pathol,2011,42(1):1-10.
[2]Snover DC, Ahnen DJ, But RW, et al.Serrated polyps of the colon and rectum and serrated polyposis[M].Pathology and Genetics Tumous and Digestive System. 2010:160-165.
[3]Goldman H,Ming S,Hickok D F.Nature and significance of hyperplastic polyps of the human colon[J].Arch Pathol,1970,89(4):349-354.
[4]U rbanski SJ,K ossakow ska A E,M arcon N,et al.Mixed hyplast ic adenomatous Polyps an underdiagnosed ent ity.Report of a case of adenocarcinoma arising within a mixed hyperplast ic adenomatous Polyp[J].Am J Surg Pat hol,1984,8(6):551-556.
[5]Longacre TA,Fenoglio Preiser CM.M ixed hyperplast ic Polyps:serated adenomas.A distinct form of colorectal neoplasia[J].Am J Surg Pathol.1990,14(5):524-527.
[6]Torlakovic E, Skovlund, Eva Ph.D Snover DC et al.Morphologic Reappraisal of Serrated Colorectal Polyps[J]. Surgical Pathology. 2003,27( 1): 65-81.
[7]Snover D C,Jass J R,Fenoglio-preiser C,et al.Serrated polyps of the Large Intestine:A Morphologic and Molecular Review of an Evolving Concept[J].AM J Clin Pathol.2005,124(3):380-391.
[8]张婉雯,任宝军,童华生等.结直肠锯齿状腺瘤内镜和病理形态学特征分析[J].中华消化内镜杂志,2006,23(2):81-85.
[9]刘成霞,贾兴芳.结直肠锯齿状腺瘤内镜表现和病理学特征分析[J].胃肠病学和肝病学杂志.2009,18(1):24-26.
[10]王鲁平,陈健,宁浩勇等.北方五所医院结直肠锯齿状病变发病情况及恶性潜能的病理学观察[C].中华医学会病理学分会2009年学术年会论文汇编, 2009.
[11]Carr NJ,Mahajan H,Tan KL,et al.Serrated and non-serrated polyps of the colorectum:their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma[J].J Clin Pathol.2009,62(6):516-518
[12]Denis B,Peters C,Chapelain C,et al.Diagnostic accuracy of community pathologists in the interpretation of colorectal polyps[J].Eur J Gastroenterol Hepatol,2009,21(10):1153-1160.
[13]Wallace K,Grau MV,Ahnen D,et al.The Association of Lifestyle and Dietary Factors with the Riskfor Serrated Polyps of the Colorectum[J].Cancer Epidemiol Biomarkers Prev. 2009,18(8):2310-7.
[14]Anderson JC,Pleau DC,Rajan TV,et al.Increased frequency of serrated aberrant crypt foci among smokers[J].Am J Gastroenterol.2010,105(7):1648-54.
[15] Kudo S,Lambert R,Allen JI,et al.Nonpolypoid neoplastic lesions of the colorectal mucosa[J].Gastrointest Endosc. 2008,68(4):S3-47.
[16]Noffsinger AE.Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol. 2009,4:343–364
[17]Hamilton S, Vogelstein B, Kudo S et alCarcinoma of the colon and rectum[M]. Pathology and genetics tumors of the digestive system. 2000:105–143.
[18]Azimuddin K,Stasik JJ,Khubchandani IT,et al.Hyperplastic polyps:―more than meets the eye‖? Report of sixteen cases. Dis Colon Rectum[J].2000,43(9):1309–1313.
[19]Warner AS,Glick ME,Fogt F,et al.Multiple large hyperplastic polyps of the colon coincident with adenocarcinoma[J]. Am J Gastroenterol.1994,89(1):123–125.
[20]Torlakovic E,Skovlund E,Snover DC,et al.Morphologic reappraisal of serrated colorectal polyps[J].Am J Surg Pathol.2003,27(1):65–81.
[21]Aust DE,Baretton GB.Serrated polyps of the colon and rectum (hyperplastic polyps, sessile serrated adenomas, traditional serrated adenomas,and mixed polyps)—proposal for diagnostic criteria[J].2010,457(3):291-7.
[22]Gurudu SR,Heigh RI,De Petris G,et al. Sessile serrated adenomas:demographic,endoscopic and pathological characteristics[J].World J Gastroenterol. 2010,16(27):3402-5.
[23]Jass JR.Classification of colorectal cancer based on correlation of clinical, morphological and molecular features[J].Histopathology.2007,50(1):113–130.
[24]Kudo S,Lambert R,Allen JI,et al.Nonpolypoid neoplastic lesions of the colorectal mucosa[J]. Gastrointest Endosc.2008,68(4):S3–47.
[25]Owens SR, Chiosea SI, Kuan SF. Selective expression of gastric mucin MUC6 in colonic sessile serrated adenoma but not in hyperplastic polyp aids in morphological diagnosis of serrated polyps[J]. Mod Pathol.2008,21(6):660–669.
[26]Bartley AN, Thompson PA, Buckmeier JA, et al.Expression of gastric pyloric mucin, MUC6, in colorectal serrated polyps[J]. Mod Pathol.2010,23(2):169–176.
[27]O'Brien MJ, Yang S, Clebanoff JL, et al..Hyperplastic (serrated) polyps of the colorectum: relationship of CpG island methylator phenotype and K-ras mutation to location and histologic subtype[J]. Am J Surg Pathol. 2004,28(4):423-34.
[28]Snover DC.Update on the serrated pathway to colorectal carcinoma[J].Hum Pathol. 2011,42(1):1-10.
[29]Hamilton SR, Bosman FT. et al.Carcinoma of the colon and rectum[M].WHO Classification of Tumours of the Digestive System.Pathology and Genetics Tumous and Digestive System.2010:134-146
[30]Leggett B, Whitehall V.Role of the serrated pathway in colorectal cancer pathogenesis[J]. Gastroenterology. 2010 ,138(6):2088-100.
[31]Ku JL,Kang SR,Shin YK,et al.Promoter hypermethylation down regulates RUNX3 gene expression in colorectal cancer cell lines[J].Oncogene.2004,23(40):6763.
[32]Subramaniam MM,Chan JY,Soonq R.RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis[J].Am J Gastroenterol.2009,104(2):426.
[33]Toribara NW,Roberton AM,Ho SB,et al.Human gastric mucin:identification of a unique species by expression cloning[J].J B io l Chem.1993,268(8):5879-5885.
[34]Percinel S,Savas B.Mucins in the colorectal neoplastic spectrum with reference to conwentional and serrated adenomas[J].Turk J Gastroenterol.2007,18(4):230-8.
[35]Haruka Hirono,Yoichi Ajioka,Hidenobu Watanabe.Bidirectional gastric differentiation in cellular mucin Phenotype (foveolar and Pyloric) in serrated adenoma and hyperplastic Poly of the colorectum[J].Pathology Iniernational.2004,54(6):401-407.
[36]Fujita K,Hirahashi M,Yamamoto H,et al.Mucin core protein expression in serrated polyps of the large intestine[J].Virchows Arch. 457(4):443-9.
[1]Odze RD.Medscape.Barrett esophagus:histology and pathology for the clinician[J].Nat Rev Gastroenterol Hepatol,2009,6(8):478-90.
[2]Bani-Hani KE, Bani-Hani BK.Columnar-lined esophagus: time to drop the eponym of "Barrett": Historical review[J].J Gastroenterol Hepatol,2008,23(5):707-15.
[3]Kouzu T, Yoshimura S, Onuma EK,et al.Barrett's esophagus[J].Nippon Geka Gakkai Zasshi,1998,99(9):552-7.
[4]Skinner D B,Walther B C,Ridder R H,et al.Barrett's esophagus:comparison of benign and malignant cases[J].Ann Surg,1983,198(4):554-65.
[5]Sampliner RE.The practice parameters comminer of the Ameri-can College of Gastroenterology:Practice guidelines on the dia-gnosis,surveillance,and therapy of Barrett's esophagus[J].Am J Gastroenterol,1998,93(7):1028.
[6]小森真人;後藤英子.Barrett上皮的发生机制[J].日本医学介绍,2002,23(1):5.
[7]Cecilia M,AMY E,Grant N,et al.Gastrointestinal Pathology[M].Third Edition.Philadelphia:Lippincott Williams & Wilkins,2008:62.
[8]Robert D.Odze.Barrett esophagus: histology and pathology for the clinician[J].Nat Rev Gastroenterol Hepatol,2009,6(8):478-90.
[9]Riddell RH, Odze RD. Definition of Barrett's esophagus: time for a rethink--is intestinal metaplasia dead?[J].Am J Gastroenterol,2009,104(10):2588-94.
[10]Chang CY, Lee YC, Lee CT, et al.The application of Prague C and M criteria in the diagnosis of Barrett's esophagus in an ethnic Chinese population[J].Am J Gastroenterol,2009,104(1):13-20.
[11]Tseng PH, Lee YC, Chiu HM, et al. Prevalence and clinical characteristics of Barrett’s esophagus in a Chinese general population[J]. J Clin Gastroenterol,2008,42(10):1074-9.
[12]Chen X, Zhu LR, Hou XH.The characteristics of Barrett's esophagus: an analysis of 4120 cases in China[J].Dis Esophagus,2009,22(5):475.
[13]Nir Modiano,Lauren B Gerson.Barrett’s esophagus Incidence, etiology, pathophysiology, prevention and treatment[J].Ther Clin Risk Manag,2007,3(6): 1035–1145.
[14]Gordon C, Kang JY, Neild PJ, Maxwell JD. The role of the hiatus hernia in gastro-oesophageal reflux disease[J].Aliment Pharmacol Ther,2004;20(7):719-32.
[15]Kuo CJ, Lin CH, Liu NJ,et al.Frequency and Risk Factors for Barrett's Esophagus in Taiwanese Patients: A Prospective Study in a Tertiary Referral Center[J].Dig Dis Sci,2009:872-877
[16]Sharma P, Vakil N. Helicobacter pylori and reflux disease.Aliment Pharmacol Ther[J]. 2003,17(3):297-305.
[17]Rubenstein JH, Dahlkemper A, Kao JY, et al.A pilot study of the association of low plasma adiponectin and Barrett's esophagus[J].Am J Gastroenterol,2008,103(6):1358-64.
[18]Edelstein Z R, Farrow D C, Bronner M P, et al.Central adiposity and risk of Barrett's esophagus[J].Gastroenterology,2007,133(2):403-11.
[19]王鲁平.胃食管交接部黏膜活检病理诊断的进展[J].诊断病理学杂志,2010,(3):.
[20]fferhaus GJ,Correa P,van Eeden S,et al.Report of an Amsterdam working group on Barrett esophagus[J].Virchows Arch,2003,443(5):602-608.
[21]Sharma P,McQuaid K,Dent J,et al.A critical review of the diagnosis and management of Barrett’s esophagus:the AGA Chicago Workshop[J].Gastroenterology,2004,127(1):310-330.
[22]Odze RD.Pathology of the gastroesophageal junction[J].Semin Diagn Pathol,2005,22(4):256-65.
[23]Odze RD, Glickman JN.Significance of squamous metaplasia-like change in the esophagus[J].Am J Surg Pathol,2005,29(9):1259-61.
[24]Odze RD.Diagnostic approach to biopsies of gastroesophageal junction[J].Pathology Case Reviews,2008,13(5):172-179.
[25]王鲁平,虞积耀,丁华野.食管胃交界部位病变[J].临床与实验病理学杂志,2004,20(6):647-649.
[26]Xue Ying Shi, MD, PhD,et al.CDX2 and Villin Are Useful Markers of Intestinal Metaplasia in the Diagnosis of Barrett Esophagus[J].Am J Clin Pathol,2008,129(4):571-577.
[27]Cantarelli JC Jr, Fagundes RB, Meurer L,et al.Immunoreactivity of cytokeratins 7 and 20 in goblet cells and columnar blue cells in patients with endoscopic evidence of Barrett's esophagus[J].Arq Gastroenterol,2009,46(2):127-31.
[28]J.R.Goldblum.Ultrashort-segment Barrett’s oesophagus, carditis and intestinalmetaplasia at the oesophagogastric junction: pathology, causation and implications[J].Current Diagnostic Pathology,2003,9(4):228--234.
[29]Chandrasoma P.Controversies of the cardiac mucosa and Barrett's oesophagus[J].Histopathology, 2005,46(4):361-73.
[30]Noffsinger A E.Defining Cancer Risk in Barrett’s Esophagus:A Pathologist’s Perspective[J].Gastrointest Cancer Res,2008,2(6):308-10.
[31]M.Hage, P.D.Siersema, H.van Dekken. Oesophageal pathology following ablation of Barrett’s mucosa[J].Current Diagnostic Pathology,2006,12(2):127–135.
[32]Philip V Kaye,Syeda A Haider,Mohammed Ilyas,et al.Barrett’s dysplasia and the Vienna classification:reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry[J].Histopathology,2009,54(6):699-712.
[33]Herman van Dekken, MD, PhD,et al.Immunohistochemical Evaluation of a Panel of Tumor Cell Markers During Malignant Progression in Barrett Esophagus[J]. Am J Clin Pathol,2008,130(5):745-53.
[34]Rossi E, Grisanti S, Villanacci V, et al.Her-2 overexpression/amplification in Barrett's esophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic Study[J].J Cell Mol Med, 2008, 13(9):3826-3833.
[35]Darlavoix T, Seelentag W, Yan P, Bachmann A, et al.Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma[J].Virchows Arch,2009,454(6):629-37.
[36]Goodarzi M, Correa AM, Ajani JA, et al.Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma[J].Mod Pathol,2009, 22(12):1612-1621.
[2] Snover DC, Ahnen DJ, But RW, et al.Serrated polyps of the colon and rectum and serrated polyposis[M].Pathology and Genetics Tumous and Digestive System. 2010:160-165.
[3]Li QL,Ito K,Sakakura C,et al.Causal relationship between the loss of RUNX3 expression and gastric cancer[J].Cell,2002,109(1):113-124.
[4]Manish M.Subramaniam MD,Jason Y,et al.RUNX3 Inactivation in Colorectal Polyps Arising Through Different Pathways of Colonic Carcinogenesis[J].Am J Gastroenterol,2009, 104(2):426-436.
[5]王鲁平,杨光之,周志勇等.结直肠锯齿状病变104例形态学及细胞增殖活性的观察[J].中华病理学杂志,2009,38(2): 100-105.
[6]Hamilton S, Vogelstein B, Kudo S,et al.Carcinoma of the colon and rectum[M]. Pathology and genetics tumors of the digestive system. 2000:105–143.
[7]Aust DE,Baretton GB.Serrated polyps of the colon and rectum (hyperplastic polyps, sessile serrated adenomas, traditional serrated adenomas,and mixed polyps)—proposal for diagnostic criteria[J].Virchows Arch,2010,457(3):291-297.
[8]Jass JR.Classification of colorectal cancer based on correlation of clinical, morphological and molecular features[J].Histopathology.2007,50(1):113–130.
[9]Kudo S,Lambert R,Allen JI,et al.Nonpolypoid neoplastic lesions of the colorectal mucosa[J]. Gastrointest Endosc.2008,68(4):S3–47.
[10]Torlakovic EE,Gomez JD,Driman DK,et al.Sessile serrated adenoma(SSA) vs traditional serrated adenoma(TSA)[J].Am J Surg Pathol,2008,32(1):21-29.
[11]East JE,Saunders BP,Jass JR.Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon:classification,molecular genetics,natural history,and clinical management[J].Gastroenterol Clin North Am,2008,37(1):25-46.
[12]王鲁平,陈健.与癌密切相关结直肠广基锯齿状腺瘤(SSA)的概念及病理诊断要点[J].诊断病理学杂志,2008,15(2):84-87.
[13]Changcun Guo, Fangfang Yao, Kaichun Wu,et al. Chromatin immunoprecipitation and association study revealed a possible role of Runt-related transcription factor 3 in the ulcerative colitis of Chinese population s[J]. Clinical Immunology,2010,135(3):483–489.
[14]许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,199,6(4):229-231.
[15]Ito Y,Miyazono K.RUNX transcription factors as key targets of TGF-beta superfamily signaling[J].Curr Opin Genet Dev,2003,13(1):43-47.
[16]Praml C,Finke LH,Herfarth C,et al.Deletion mapping defines different regions in 1p34.2-pter that may harbor genetic information related to human colorectal cancer[J]. Oncogene,1995,11(7):1357-62.
[17]Inoue K,Ozaki S,Shiga T,et al.Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons[J].Nat Neurosci,2002,5(10):946-954.
[18]Woolf E,Xiao C,Fainaru O,et al.Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis[J].Proc Natl Acad Sci U S A,2003,100(13):7731-7736.
[19]Levanon D,Bettoun D,Harris-Cerruti C,et al.The Runx3 transcription factor regulates development and survival of TrkC dorsal root ganglia neurons[J].EMBO J,2002,21(13):3454-3463.
[20]Markowitz SD,Roberts AB.Tumor suppressor activity of the TGF-beta pathway in human cancers[J].Cytokine Growth Factor Rev,1996,7(1):93-102.
[21]Zaidi SK,Sullivan AJ,van W ijnen AJ,et al.Integration of Runx and Smad regulatory signals at transcrip ttionally active subnuclear sites[J].Proc Natl Acad Sci USA,2002,99(12):8048-8053.
[22]Goel A,Arnold CN,Tassone P,et al.Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers[J].Int J Cancer,2004,112(5):754-759.
[23]Ku JL,Kang SB,Shin YK.et al.Promoter hypermethylation downregulates RUNX3 gene expression in colorectal cancer cell lines[J].Oncogene,2004,23(40):6736-6742.
[24]Imamura Y,Hibi K,Koike M,et al.RUNX3 promoter region is specifically methylated in poorly-differentiated colorectal cancer[J].Anticancer Res,2005,25(4):2627-2630.
[25]Schulmann K,Sterian A,Berki A et al. Inactivation of p16,RUNX3,and HPP1 occurs early in Barrett’s-associated neoplastic progression and predicts progression risk[J].Oncogene,2005, 24(25):4138-4148.
[26]Park WS,Cho YG,Kim CJ,et al.Hypermethylation of the RUNX3 gene in hepatocellular carcinoma[J].Exp Mol Med,2005,37(4):276-281.
[27]Takahashi T,Shivapurkar N,Riquelme E.et al.Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis[J].Clin Cancer Res,2004,10(18pt1):6126-6133.
[28]Subramaniam MM,Chan JY,Soong R,et al.RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression[J].Breast Cancer Res Treat.2009,113(1):113-121.
[29]Yanada M,Yaoi T,Shimada J,et al.Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines[J].Oncol Rep,2005,14(4):817-822.
[30]Salto-Tellez M,Peh BK,Ito K.et al.RUNX3 protein is overexpressed in human basal cellcarcinomas[J].Oncogene,2006;25(58):7646-7649.
[31]李华,党荣良,袁权利等结肠癌组织中runx3、突变型p53蛋白的表达变化及意义[J].山东医药.2010,26 (50):56.
[32]Ito K,Liu Q,Salto-Tellez M,et al.RUNX3,a novel tumor suppressor,is frequently inactivated in gastric cancer by protein mislocalization[J].Cancer Res,2005,65(17):7743-7750.
[33]Lau QC,Raja E,Salto-Tellez M,et al.RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer[J]. Cancer Res,2006,66(13):6512-6520.
[34]Xu L,Massague J.Nucleocytoplasmic shuttling of signal transducers[J].Nat Rev Mol Cell Biol,2004,5(3):209-219.
[35]Tebutt NC,Giraud AS,Inglese M,et al.Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp 130 mutant mice[J].Nat Med,2002,8(10):1089-1097.
[1]Snover DC, Jass JR, Fenoglio-Preiser C, et al.Serrated polyps of the large intestine:a morphologic and molecular review of an evolving concept[J]. Am J Clin Pathol, 2005,124 (3):380-391.
[2]East JE, Saunders BP, Jass JR.Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon:classification,molecular genetics,natural history,and clinical management[J]. Gastroenterol Clin N Am,2008,37(1):25-46.
[3]Farris AB, Misdraji J, Srivastava A,et al. Sessile serrated adenoma:challenging discrimination from other serrated colonic polyps[J].Am J Surg Pathol,2008,32(1):30-35.
[4] Fred T Bosman,Fatima Carrneiro,Ralph H Hruban,et al.WHO Classification of Tumours of the Digestive System[M].International Agency for Research on Cancer,Lyon,2010:160-165.
[5] Yantiss RK, Oh KY, Chen YT,et al.Filiform serrated adenomas:a clinicopathologic and immunophenotypic study of 18 cases[J].Am J Surg Pathol,2007,31(8):1238-45.
[6] Owens SR,Chiosea SI,Kuan SF.Selective expression of gastric mcolonic sessile serrated adenoma hyperplastic polyp aids in morpdiagnosis of serrated polyps[J].Mod Pathol,2008,21 (6):660-9.
[7] Torlakovic EE,Gomez JD,Driman DK,et al.Sessile serrated adenoma(SSA) vs traditional serrated adenoma(TSA)[J].Am J Surg Pathol,2008,32(1):21-29.
[8] East JE,Saunders BP,Jass JR.Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon:classification,molecular genetics,natural history,and clinical management[J].Gastroenterol Clin North Am,2008,37(1):25-46.
[9]王鲁平,杨光之,周志勇等.结直肠锯齿状病变104例形态学及细胞增殖活性的观察[J].中华病理学杂志, 2009, 38(2): 100-105.
[10]王鲁平,陈健.与癌密切相关结直肠广基锯齿状腺瘤(SSA)的概念及病理诊断要点[J].诊断病理学杂志, 2008, 15(2):84-87.
[11] Maruyama K,Ochiai A,Akimoto S,et al.Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer[J].Oncology,2000,59(4):302-309.
[12]许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志, 1996, 6(4): 229-231.
[13]王鲁平,陈健,宁浩勇等.结直肠锯齿状病变发病情况及恶性潜能的病理学观察[J].中华病理学杂志,2010,39(7):447-451.
[14]Hiyama T,Yokozaki H,Shimamoto F,et al.Frequent p53 gene mutations in serrated adenomasof the colorectum[J].J Pathol,1998,186(2):131～139.
[15] Hiyama T,Yokozaki H,Shimamoto F,et al.Frequent p53 gene mutations in serrated adenomas of the colorectum[J].J Pathol,1998,186(2):131-139.
[16] Tateyama H,Li W,Takahashi E,et al.Apoptosis index and apoptosisrelated antigen expression in serrated adenoma of the colorectum:the saw-toothed structure may be related to inhibition of apoptosis[J].Am J Surg Pathol,2002,26(2):249-256.
[17]张宇,唐仁泉,张学义,等.p53、Bcl-2蛋白在锯齿状腺瘤的表达及临床意义[J].中外医疗,2008,24:61-62.
[18]代小娟,韩英,王鲁平.结直肠锯齿状腺瘤癌变潜能的研究[J].实用癌症杂志.2009,24 (5):548-550
[19] Oh K,Redston M,Odze RD.Support for hMLH1 and MGMT silencing as a mechanism of tumorigenesis in the hyperplasticadenoma-carcinoma(serrated) carcinogenic pathway in the colon[J].Hum Pathol,2005,36(1):101-111.
[20]Kirchner T, Muller S,Hattori T,ea tl.Metaplasia,intraepithelial neoplasia and early cancer of the stomach are related to differentiated epithelial cells defined by cytokeration-7 expressions in gastritis[J].Virchows Arch,2001,439(4):51-52.
[21]Tatsumi N, Mukaisho K,Mitsufuji S,ea tl. Expression of cytokeratins 7 and 20 in serrated adenoma and related diseases[J]. Dig Dis Sci, 2005,50(9):1741-1746.
[22]PeiferM.Wnt signaling in oneogenesis and embryogenesis a look outside the nucleus[J].Science,2000,287(5458):1606-1609.
[23]Hugh TJ,Dillon SA,Taylor BA,etal.Cadherin-catenin in espression in primary colorectal cancer:a survival analysis[J].Br J Cancer,1999,80(7):1046-1051.
[24]WongSC,LoES,LeeKC,et al.Prognostic and diagnostic significance of bête-catenin nuclear inmunostaining in colorectal cancer[J].Clin Caneer Res,2004,10(4):1401-1408.
[25]SuhE,Traber P.An intestine-specific homeobox gene regulates proliferation and differentiation[J].Mol Cel Biol,1996,16:619-625.
[26]Bla YQ,Miyake S,Iwai T,et a1.CDX2,a homoebox transcription factor,upregulates transcription of the p21/WAF1/C1P1gene [J].Oncogene,2003,22:7942-7949.
[27]Kim SP,Park JW,Lee SH,et a1.Homeodomain protein CDX2 regulates COX2 expression in colorectal cancer[J].Biochem Bio-phys Res Commun,2004,315:93—99.
[28] mamichi N,Inada K,Furukawa C,et al.Cdx2 and the Brm-type SWI/SNF complex cooperatively regulate villin expression in gastrointestinal cells[J].Exp Cell Res,2009,315 (10):1779-1789
[29] Gross I,Duluc I,Benameur T,et al.The intestine-specific homeobox gene Cdx2 decreases mobility and antagonizes dissemination of colon cancer cells[J].Oncogene,2008,27(1):107-115.
[30] Li QL,Ito K,Sakakura C,et al.Causal relationship between the loss of RUNX3 expression and gastric cancer[J].Cell,2002,109(1):113-124.
[31]Zaidi SK,Sullivan AJ,van W ijnen AJ,et al.Integration of Runx and Smad regulatory signals at transcrip ttionally active subnuclear sites[J].Proc Natl Acad Sci USA,2002,99(12):8048-8053.
[32] Subramaniam MM,Chan JY,Soonq R.RUNX3 inactivation in colorectal polyp s arising through different pathways of colonic carcinogenesis[J].Am J Gastroenterol,2009,104(2):426.
[1]Snover DC. Update on the serrated pathway to colorectal carcinoma[J].Hum Pathol,2011,42(1):1-10.
[2]Snover DC, Ahnen DJ, But RW, et al.Serrated polyps of the colon and rectum and serrated polyposis[M].Pathology and Genetics Tumous and Digestive System. 2010:160-165.
[3]Goldman H,Ming S,Hickok D F.Nature and significance of hyperplastic polyps of the human colon[J].Arch Pathol,1970,89(4):349-354.
[4]U rbanski SJ,K ossakow ska A E,M arcon N,et al.Mixed hyplast ic adenomatous Polyps an underdiagnosed ent ity.Report of a case of adenocarcinoma arising within a mixed hyperplast ic adenomatous Polyp[J].Am J Surg Pat hol,1984,8(6):551-556.
[5]Longacre TA,Fenoglio Preiser CM.M ixed hyperplast ic Polyps:serated adenomas.A distinct form of colorectal neoplasia[J].Am J Surg Pathol.1990,14(5):524-527.
[6]Torlakovic E, Skovlund, Eva Ph.D Snover DC et al.Morphologic Reappraisal of Serrated Colorectal Polyps[J]. Surgical Pathology. 2003,27( 1): 65-81.
[7]Snover D C,Jass J R,Fenoglio-preiser C,et al.Serrated polyps of the Large Intestine:A Morphologic and Molecular Review of an Evolving Concept[J].AM J Clin Pathol.2005,124(3):380-391.
[8]张婉雯,任宝军,童华生等.结直肠锯齿状腺瘤内镜和病理形态学特征分析[J].中华消化内镜杂志,2006,23(2):81-85.
[9]刘成霞,贾兴芳.结直肠锯齿状腺瘤内镜表现和病理学特征分析[J].胃肠病学和肝病学杂志.2009,18(1):24-26.
[10]王鲁平,陈健,宁浩勇等.北方五所医院结直肠锯齿状病变发病情况及恶性潜能的病理学观察[C].中华医学会病理学分会2009年学术年会论文汇编, 2009.
[11]Carr NJ,Mahajan H,Tan KL,et al.Serrated and non-serrated polyps of the colorectum:their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma[J].J Clin Pathol.2009,62(6):516-518
[12]Denis B,Peters C,Chapelain C,et al.Diagnostic accuracy of community pathologists in the interpretation of colorectal polyps[J].Eur J Gastroenterol Hepatol,2009,21(10):1153-1160.
[13]Wallace K,Grau MV,Ahnen D,et al.The Association of Lifestyle and Dietary Factors with the Riskfor Serrated Polyps of the Colorectum[J].Cancer Epidemiol Biomarkers Prev. 2009,18(8):2310-7.
[14]Anderson JC,Pleau DC,Rajan TV,et al.Increased frequency of serrated aberrant crypt foci among smokers[J].Am J Gastroenterol.2010,105(7):1648-54.
[15] Kudo S,Lambert R,Allen JI,et al.Nonpolypoid neoplastic lesions of the colorectal mucosa[J].Gastrointest Endosc. 2008,68(4):S3-47.
[16]Noffsinger AE.Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol. 2009,4:343–364
[17]Hamilton S, Vogelstein B, Kudo S et alCarcinoma of the colon and rectum[M]. Pathology and genetics tumors of the digestive system. 2000:105–143.
[18]Azimuddin K,Stasik JJ,Khubchandani IT,et al.Hyperplastic polyps:―more than meets the eye‖? Report of sixteen cases. Dis Colon Rectum[J].2000,43(9):1309–1313.
[19]Warner AS,Glick ME,Fogt F,et al.Multiple large hyperplastic polyps of the colon coincident with adenocarcinoma[J]. Am J Gastroenterol.1994,89(1):123–125.
[20]Torlakovic E,Skovlund E,Snover DC,et al.Morphologic reappraisal of serrated colorectal polyps[J].Am J Surg Pathol.2003,27(1):65–81.
[21]Aust DE,Baretton GB.Serrated polyps of the colon and rectum (hyperplastic polyps, sessile serrated adenomas, traditional serrated adenomas,and mixed polyps)—proposal for diagnostic criteria[J].2010,457(3):291-7.
[22]Gurudu SR,Heigh RI,De Petris G,et al. Sessile serrated adenomas:demographic,endoscopic and pathological characteristics[J].World J Gastroenterol. 2010,16(27):3402-5.
[23]Jass JR.Classification of colorectal cancer based on correlation of clinical, morphological and molecular features[J].Histopathology.2007,50(1):113–130.
[24]Kudo S,Lambert R,Allen JI,et al.Nonpolypoid neoplastic lesions of the colorectal mucosa[J]. Gastrointest Endosc.2008,68(4):S3–47.
[25]Owens SR, Chiosea SI, Kuan SF. Selective expression of gastric mucin MUC6 in colonic sessile serrated adenoma but not in hyperplastic polyp aids in morphological diagnosis of serrated polyps[J]. Mod Pathol.2008,21(6):660–669.
[26]Bartley AN, Thompson PA, Buckmeier JA, et al.Expression of gastric pyloric mucin, MUC6, in colorectal serrated polyps[J]. Mod Pathol.2010,23(2):169–176.
[27]O'Brien MJ, Yang S, Clebanoff JL, et al..Hyperplastic (serrated) polyps of the colorectum: relationship of CpG island methylator phenotype and K-ras mutation to location and histologic subtype[J]. Am J Surg Pathol. 2004,28(4):423-34.
[28]Snover DC.Update on the serrated pathway to colorectal carcinoma[J].Hum Pathol. 2011,42(1):1-10.
[29]Hamilton SR, Bosman FT. et al.Carcinoma of the colon and rectum[M].WHO Classification of Tumours of the Digestive System.Pathology and Genetics Tumous and Digestive System.2010:134-146
[30]Leggett B, Whitehall V.Role of the serrated pathway in colorectal cancer pathogenesis[J]. Gastroenterology. 2010 ,138(6):2088-100.
[31]Ku JL,Kang SR,Shin YK,et al.Promoter hypermethylation down regulates RUNX3 gene expression in colorectal cancer cell lines[J].Oncogene.2004,23(40):6763.
[32]Subramaniam MM,Chan JY,Soonq R.RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis[J].Am J Gastroenterol.2009,104(2):426.
[33]Toribara NW,Roberton AM,Ho SB,et al.Human gastric mucin:identification of a unique species by expression cloning[J].J B io l Chem.1993,268(8):5879-5885.
[34]Percinel S,Savas B.Mucins in the colorectal neoplastic spectrum with reference to conwentional and serrated adenomas[J].Turk J Gastroenterol.2007,18(4):230-8.
[35]Haruka Hirono,Yoichi Ajioka,Hidenobu Watanabe.Bidirectional gastric differentiation in cellular mucin Phenotype (foveolar and Pyloric) in serrated adenoma and hyperplastic Poly of the colorectum[J].Pathology Iniernational.2004,54(6):401-407.
[36]Fujita K,Hirahashi M,Yamamoto H,et al.Mucin core protein expression in serrated polyps of the large intestine[J].Virchows Arch. 457(4):443-9.
[1]Odze RD.Medscape.Barrett esophagus:histology and pathology for the clinician[J].Nat Rev Gastroenterol Hepatol,2009,6(8):478-90.
[2]Bani-Hani KE, Bani-Hani BK.Columnar-lined esophagus: time to drop the eponym of "Barrett": Historical review[J].J Gastroenterol Hepatol,2008,23(5):707-15.
[3]Kouzu T, Yoshimura S, Onuma EK,et al.Barrett's esophagus[J].Nippon Geka Gakkai Zasshi,1998,99(9):552-7.
[4]Skinner D B,Walther B C,Ridder R H,et al.Barrett's esophagus:comparison of benign and malignant cases[J].Ann Surg,1983,198(4):554-65.
[5]Sampliner RE.The practice parameters comminer of the Ameri-can College of Gastroenterology:Practice guidelines on the dia-gnosis,surveillance,and therapy of Barrett's esophagus[J].Am J Gastroenterol,1998,93(7):1028.
[6]小森真人;後藤英子.Barrett上皮的发生机制[J].日本医学介绍,2002,23(1):5.
[7]Cecilia M,AMY E,Grant N,et al.Gastrointestinal Pathology[M].Third Edition.Philadelphia:Lippincott Williams & Wilkins,2008:62.
[8]Robert D.Odze.Barrett esophagus: histology and pathology for the clinician[J].Nat Rev Gastroenterol Hepatol,2009,6(8):478-90.
[9]Riddell RH, Odze RD. Definition of Barrett's esophagus: time for a rethink--is intestinal metaplasia dead?[J].Am J Gastroenterol,2009,104(10):2588-94.
[10]Chang CY, Lee YC, Lee CT, et al.The application of Prague C and M criteria in the diagnosis of Barrett's esophagus in an ethnic Chinese population[J].Am J Gastroenterol,2009,104(1):13-20.
[11]Tseng PH, Lee YC, Chiu HM, et al. Prevalence and clinical characteristics of Barrett’s esophagus in a Chinese general population[J]. J Clin Gastroenterol,2008,42(10):1074-9.
[12]Chen X, Zhu LR, Hou XH.The characteristics of Barrett's esophagus: an analysis of 4120 cases in China[J].Dis Esophagus,2009,22(5):475.
[13]Nir Modiano,Lauren B Gerson.Barrett’s esophagus Incidence, etiology, pathophysiology, prevention and treatment[J].Ther Clin Risk Manag,2007,3(6): 1035–1145.
[14]Gordon C, Kang JY, Neild PJ, Maxwell JD. The role of the hiatus hernia in gastro-oesophageal reflux disease[J].Aliment Pharmacol Ther,2004;20(7):719-32.
[15]Kuo CJ, Lin CH, Liu NJ,et al.Frequency and Risk Factors for Barrett's Esophagus in Taiwanese Patients: A Prospective Study in a Tertiary Referral Center[J].Dig Dis Sci,2009:872-877
[16]Sharma P, Vakil N. Helicobacter pylori and reflux disease.Aliment Pharmacol Ther[J]. 2003,17(3):297-305.
[17]Rubenstein JH, Dahlkemper A, Kao JY, et al.A pilot study of the association of low plasma adiponectin and Barrett's esophagus[J].Am J Gastroenterol,2008,103(6):1358-64.
[18]Edelstein Z R, Farrow D C, Bronner M P, et al.Central adiposity and risk of Barrett's esophagus[J].Gastroenterology,2007,133(2):403-11.
[19]王鲁平.胃食管交接部黏膜活检病理诊断的进展[J].诊断病理学杂志,2010,(3):.
[20]fferhaus GJ,Correa P,van Eeden S,et al.Report of an Amsterdam working group on Barrett esophagus[J].Virchows Arch,2003,443(5):602-608.
[21]Sharma P,McQuaid K,Dent J,et al.A critical review of the diagnosis and management of Barrett’s esophagus:the AGA Chicago Workshop[J].Gastroenterology,2004,127(1):310-330.
[22]Odze RD.Pathology of the gastroesophageal junction[J].Semin Diagn Pathol,2005,22(4):256-65.
[23]Odze RD, Glickman JN.Significance of squamous metaplasia-like change in the esophagus[J].Am J Surg Pathol,2005,29(9):1259-61.
[24]Odze RD.Diagnostic approach to biopsies of gastroesophageal junction[J].Pathology Case Reviews,2008,13(5):172-179.
[25]王鲁平,虞积耀,丁华野.食管胃交界部位病变[J].临床与实验病理学杂志,2004,20(6):647-649.
[26]Xue Ying Shi, MD, PhD,et al.CDX2 and Villin Are Useful Markers of Intestinal Metaplasia in the Diagnosis of Barrett Esophagus[J].Am J Clin Pathol,2008,129(4):571-577.
[27]Cantarelli JC Jr, Fagundes RB, Meurer L,et al.Immunoreactivity of cytokeratins 7 and 20 in goblet cells and columnar blue cells in patients with endoscopic evidence of Barrett's esophagus[J].Arq Gastroenterol,2009,46(2):127-31.
[28]J.R.Goldblum.Ultrashort-segment Barrett’s oesophagus, carditis and intestinalmetaplasia at the oesophagogastric junction: pathology, causation and implications[J].Current Diagnostic Pathology,2003,9(4):228--234.
[29]Chandrasoma P.Controversies of the cardiac mucosa and Barrett's oesophagus[J].Histopathology, 2005,46(4):361-73.
[30]Noffsinger A E.Defining Cancer Risk in Barrett’s Esophagus:A Pathologist’s Perspective[J].Gastrointest Cancer Res,2008,2(6):308-10.
[31]M.Hage, P.D.Siersema, H.van Dekken. Oesophageal pathology following ablation of Barrett’s mucosa[J].Current Diagnostic Pathology,2006,12(2):127–135.
[32]Philip V Kaye,Syeda A Haider,Mohammed Ilyas,et al.Barrett’s dysplasia and the Vienna classification:reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry[J].Histopathology,2009,54(6):699-712.
[33]Herman van Dekken, MD, PhD,et al.Immunohistochemical Evaluation of a Panel of Tumor Cell Markers During Malignant Progression in Barrett Esophagus[J]. Am J Clin Pathol,2008,130(5):745-53.
[34]Rossi E, Grisanti S, Villanacci V, et al.Her-2 overexpression/amplification in Barrett's esophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic Study[J].J Cell Mol Med, 2008, 13(9):3826-3833.
[35]Darlavoix T, Seelentag W, Yan P, Bachmann A, et al.Altered expression of CD44 and DKK1 in the progression of Barrett's esophagus to esophageal adenocarcinoma[J].Virchows Arch,2009,454(6):629-37.
[36]Goodarzi M, Correa AM, Ajani JA, et al.Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma[J].Mod Pathol,2009, 22(12):1612-1621.